市场调查报告书

医药品中间体的全球市场 (2020年~2027年)

Global Pharmaceutical Intermediates Market - 2020-2027

出版商 DataM Intelligence 商品编码 968992
出版日期 内容资讯 英文
商品交期: 最快1-2个工作天内
价格
医药品中间体的全球市场 (2020年~2027年) Global Pharmaceutical Intermediates Market - 2020-2027
出版日期: 2020年11月04日内容资讯: 英文
简介

随著慢性病患者人数的增加以及世界各地人口的老龄化,对原料药(API)的需求正在增加,这导致了药物中间体市场的增长。此外,主要制造商的生产和投资活动也越来越活跃。另一方面,每个国家加强法规的动向以及由于新的冠状病毒感染(COVID-19)的传播而导致的供应链中断尤其可能会阻碍市场增长。

本报告提供全球医药品中间体的市场相关分析,提供市场基本结构及最新形势,整体市场趋势预测 (今后8年份),各类型·各用途·各终端用户及地区别详细趋势,主要的推动及阻碍市场要素,市场竞争结构,主要企业的简介·事业策略等相关调查。

目录

第1章 全球医药品中间体市场:分析方法·范围

第2章 全球医药品中间体市场:市场定义和概要

第3章 全球医药品中间体市场:摘要整理

第4章 全球医药品中间体市场:市场动态

  • 对市场的影响要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响力分析

第5章 全球医药品中间体市场:产业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法规分析
  • 医疗费偿付分析
  • 未满足需求

第6章 全球医药品中间体市场:新型冠状病毒感染疾病 (COVID-19)的分析

  • COVID-19对市场的影响分析
    • COVID-19前市场方案
    • COVID-19当今市场方案目前市场方案
    • COVID-19后未来市场方案
  • COVID-19流行中的价格趋势
  • 需求与供给的变动阶段
  • 感染扩大时政府在市场上的配合措施
  • 各制造公司的策略展开情形
  • 结论

第7章 全球医药品中间体市场:各类型

  • 简介
  • 市场规模的分析与与前一年同期相比成长率 (YoY):各类型
  • 市场向心力指数:各类型
    • 化学中间体
    • 原料药中间体
    • 自订中间体
    • 其他

第8章 全球医药品中间体市场:各用途

  • 简介
  • 市场规模的分析与与前一年同期相比成长率 (YoY):各用途
  • 市场向心力指数:各用途
    • 止痛药
    • 抗感染疾病药
    • 心血管药
    • 口服抗糖尿病药物
    • 抗菌药
    • 其他

第9章 全球医药品中间体市场:各终端用户

  • 简介
  • 市场规模的分析与与前一年同期相比成长率 (YoY):各终端用户
  • 市场向心力指数:各终端用户
    • 生物科技企业/制药企业
    • 研究机关
    • CMO (医药品受托制造厂商)
    • 其他

第10章 全球医药品中间体市场:各地区

  • 简介
  • 市场规模的分析与与前一年同期相比成长率 (YoY):各地区
  • 市场向心力指数:各地区
  • 北美
    • 简介
    • 域内市场固有趋势
    • 市场规模的分析与与前一年同期相比成长率 (YoY):各类型
    • 市场规模的分析与与前一年同期相比成长率 (YoY):各用途
    • 市场规模的分析与与前一年同期相比成长率 (YoY):各终端用户
    • 市场规模的分析与与前一年同期相比成长率 (YoY):各国
  • 欧洲
  • 南美
  • 亚太地区
  • 中东·非洲

第11章 全球医药品中间体市场:竞争情形

  • 竞争模式
  • 市场定位/占有率分析
  • 企业合并·收购 (M&A)的分析

第12章 全球医药品中间体市场:企业简介

  • Sanofi SA
    • 企业概要
    • 产品的组合/概要
    • 近几年趋势
    • 财务分析:概要
  • Aceto Corporation
  • BASF SE
  • Chiracon GmbH
  • Yin-sheng Bio-tech Co. Ltd.
  • Dishman Group
  • Green Vision Life Sciences
  • Midas Pharma GmbH
  • Vertellus Holdings LLC
  • Zydus Cadila
  • 其他的企业

第13章 全球医药品中间体市场:重要考察

第14章 关于DataM Intelligence

目录

Market Overview

The global pharmaceutical intermediates market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Pharmaceutical intermediates are the synthetic aggravates that are the building squares utilized in the generation of dynamic pharmaceutical fixings. Pharmaceutical intermediates are created amid the way toward assembling or amalgamation of dynamic pharmaceutical fixings. These pharmaceutical intermediates additionally experience sub-atomic changes and preparing before turning into a functioning pharmaceutical fixing.

Market Dynamics

The global pharmaceutical intermediates market growth is driven by the increasing use of pharmaceutical intermediates in the fundamental base part of active pharmaceutical ingredients (APIs), the market is also expected to witness upsurge in demand in forecast period.

Increasing Prevalence of Chronic Diseases is expected to drive the growth in the forecast period

The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the management of chronic diseases. For example, according to the World Health Organization (WHO), the prevalence of diabetes has surged from 108.0 million in 1980 to 422.0 million in 2014, and the number is rising rapidly.

Furthermore, according to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases. These factors are driving the growth of the market in the forecast period.

Increasing investments in manufacturing expected to drive the market growth

Leading pharmaceutical companies in pharmaceutical intermediates market have announced their intentions to invest in manufacturing facilities due to various reasons such as to enhance the production capacity of pharmaceutical intermediates, reduce corporate tax rate and to increase their global footprints as well as their presence in emerging markets.

For instance, in July 2018, Pfizer invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it had made earlier in 2018 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country. These factors are driving the growth of the market in forecast period.

Regulatory obstruction is likely to hinder the market growth

On the contrary, rising monetary pressure as well as regulatory obstruction is expected to freeze the growth of pharmaceutical intermediates market in the forecast period.

COVID-19 Impact Analysis

The disruptive effects of the coronavirus COVID-19 have placed enormous strain on the global supply of pharmaceutical intermediates, increasing the risk of shortages. Although production across various industries and regions in China has been gradually resuming since late February, U.S. pharmaceutical intermediates manufacturers, which heavily source directly and indirectly from China, are now exposed to high risks in supply shortages over the next one to two months. These risks are due primarily to limited operational capacity in China and how resumption of production will be prioritized. Thesse factors are restraning the growth of the market in the forecast period.

Segment Analysis

By application the pharmaceutical intermediates market is classified into analgesics, anti-infective drugs, cardiovascular drugs, oral antidiabetic drugs, antimicrobial drugs, others.

Cardiovascular drugs segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Cardiovascular diseases are the leading cause of deaths worldwide. According to the American College of Cardiology, cardiovascular disease (CVD) accounted for 800,000 deaths in the United States in 2017 alone. Among Americans, an average of one person dies from cardiovascular disease, every 40 seconds. Coronary heart disease (CHD) accounts for the majority of CVD deaths, followed by stroke and heart failure. According to the European Heart Network, every year, cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU).

This high prevalence of cardiovascular diseases is generating a huge demand for cardiovascular drugs, which, in turn, is expected to propel the growth in the need for various pharmaceutical intermediates. Hence, owing to the aforementioned factors, the concerned segment of the pharmaceutical intermediates market is expected to observe steady growth over the forecast period.

Analgesics segment has the positive market growth in the forecast period. Analgesics, or painkillers, are used to reduce and treat aches and pains. Internal and external analgesics are used to combat pain resulting from inflammation, cancer treatments, physiological injury, neuropathic conditions, surgeries, wounds, and phantom aches. The most prominent therapeutic classes of analgesics are local anesthesia, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids. The growing incidence of cancer worldwide and the rise in chronic diseases are mainly responsible for the consistent growth of the global analgesics market. In 2017, between 950-1000 million people were over the age of 60. However, by 2050, these numbers are expected to reach 2100 million, accounting for around 21% of the total global population. As older adults are more vulnerable to chronic and lifestyles diseases, it will significantly contribute to the sales of analgesics. Apart from this, many leading pharmaceutical companies are continually focusing on clinical advancements in both the delivery and design of analgesic drugs. They are also developing safer opioids with improved side effect profiles and effective pain relief. Moreover, the presence of a strong drug pipeline with efficacious drugs waiting for approvals by the United States Food and Drug Administration (USFDA) is further expected to enhance the use of analgesics across the globe.

Geographical Analysis

North America region holds the largest market share global Pharmaceutical Intermediates

North America region is dominating the global Pharmaceutical Intermediates accounted for the largest market share in 2019, due to the advanced research and development facilities mainly across the United States and Canada. In addition, the rising prevalence of various chronic conditions is also fueling market growth across the region. The U.S. holds the largest market for H1N1 vaccination, followed by Canada, in North America. For instance, in December 2019, NACI (National Advisory Committee on Immunization) published scientific information and recommendation on MenB-fHBP (bivalent factor-H binding protein meningococcal serogroup B) vaccine (Trumenba). The presence of a strong pipeline of meningococcal vaccines is expected to maintain a significant market share of the region.

According to the 2017 report of Health Library, Cardiovascular disease, listed as the underlying cause of death, accounts for nearly 801,000 deaths in the US. That is about 1 of every 3 deaths in the US. About 2,200 Americans die of cardiovascular disease each day, an average of 1 death every 40 seconds.

However, the Asia-Pacific market is anticipated to witness the highest growth during the forecast period, due to increasing healthcare expenditure. Additionally, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.

Competitive Landscape

The Pharmaceutical Intermediates is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aceto Corporation, BASF SE, Chiracon GmbH, Yin-sheng Bio-tech Co., Ltd., Dishman Group, Green Vision Life Sciences, Midas Pharma GmbH, Sanofi SA, Vertellus Holdings LLC., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Pharmaceutical Intermediates globally.

Sanofi S.A

Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations.

Product Portfolio: The Company's portfolio comprised of drugs, generic medicines, food supplement, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.

Why Purchase the Report?

  • Visualize the composition of the pharmaceutical intermediates market segmentation by type, application, end-user, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in pharmaceutical intermediates market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of pharmaceutical intermediates market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global pharmaceutical intermediates market report would provide an access to an approx. 62 market data table, 60 figures and 300 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Pharmaceutical Intermediates Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pharmaceutical Intermediates Market- Market Definition and Overview

3. Global Pharmaceutical Intermediates Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Application
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global Pharmaceutical Intermediates Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Chronic Diseases
      • 4.1.1.2. Growing R&D Initiatives and Activities in the Pharmaceutical Industry
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent Regulatory Issues Regarding Certain Pharmaceutical Intermediate Substances
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Pharmaceutical Intermediates Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Pharmaceutical Intermediates Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Pharmaceutical Intermediates Market - By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Chemical Intermediate*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Bulk Drug Intermediate
      • 7.3.2.1. Chiral Intermediates
      • 7.3.2.2. Achiral Intermediates
    • 7.3.3. Custom Intermediates
    • 7.3.4. Others

8. Global Pharmaceutical Intermediates Market - By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.3. Market Attractiveness Index, By Application
    • 8.3.1. Analgesics *
      • 8.3.1.1.1. Introduction
      • 8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Anti-Infective Drugs
    • 8.3.3. Cardiovascular Drugs
    • 8.3.4. Oral Antidiabetic Drugs
    • 8.3.5. Antimicrobial Drugs
    • 8.3.6. Others

9. Global Pharmaceutical Intermediates Market - By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Biotech and Pharma Companies *
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Research Institutions
    • 9.3.3. Contract manufacturing organizations
    • 9.3.4. Others

10. Global Pharmaceutical Intermediates Market- By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Pharmaceutical Intermediates Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Pharmaceutical Intermediates Market - Company Profiles

  • 12.1. Sanofi SA *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Aceto Corporation
  • 12.3. BASF SE
  • 12.4. Chiracon GmbH
  • 12.5. Yin-sheng Bio-tech Co. Ltd.
  • 12.6. Dishman Group
  • 12.7. Green Vision Life Sciences
  • 12.8. Midas Pharma GmbH
  • 12.9. Vertellus Holdings LLC
  • 12.10. Zydus Cadila

LIST NOT EXHAUSTIVE

13. Global Pharmaceutical Intermediates Market - Premium Insights

14. Global Pharmaceutical Intermediates Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us